MRNA BRAF expression helps to identify papillary thyroid carcinomas in thyroid nodules independently of the presence of BRAFV600E mutation

Pathology Research and Practice

Volumn 208, Issue 8, 2012, Pages 489-492

  Araujo, Priscila Pereira Costa ^a   Marcello, Marjory Alana ^a   Tincani, Alfio Jose ^a   Guilhen, Ana Carolina Trindade ^a   Morari, Elaine Cristina ^a   Ward, Laura Sterian ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

BRAF expression; Diagnosis; Papillary thyroid cancer

Indexed keywords

B RAF KINASE; MESSENGER RNA; TUMOR MARKER;

ADULT; ARTICLE; BRAF GENE; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PREDICTIVE VALUE; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY AND SPECIFICITY; THYROID HYPERPLASIA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; TUMOR DIFFERENTIATION; TUMOR VOLUME;

BIOPSY, FINE-NEEDLE; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; RNA, MESSENGER; THYROID NEOPLASMS; THYROID NODULE; TUMOR MARKERS, BIOLOGICAL;

EID: 84864102396     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2012.05.013     Document Type: Article

References (28)

1. Society A.C. Cancer Facts & Figures 2012 2012, American Cancer Society, Atlanta.
2. Rastogi T., Devesa S., Mangtani P., Mathew A., Cooper N., Kao R., et al. Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US. Int. J. Epidemiol. 2008, 37(February (1)):147-160.
3. Gharib H., Papini E., Paschke R. Thyroid nodules: a review of current guidelines, practices, and prospects. Eur. J. Endocrinol. 2008, 159(November (5)):493-505.
4. Pazaitou-Panayiotou K., Capezzone M., Pacini F. Clinical features and therapeutic implication of papillary thyroid microcarcinoma. Thyroid 2007, 17(November (11)):1085-1092.
5. Li H., Robinson K.A., Anton B., Saldanha I.J., Ladenson P.W. Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules. J. Clin. Endocrinol. Metab. 2011, 96(November (11)):E1719-E1726.
6. Gharib H., Papini E., Paschke R., Duick D.S., Valcavi R., Hegedus L., et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. Endocr. Pract. 2010, 16(May-June (3)):468-475.
7. Piana S., Frasoldati A., Ferrari M., Valcavi R., Froio E., Barbieri V., et al. Is a five-category reporting scheme for thyroid fine needle aspiration cytology accurate? Experience of over 18,000 FNAs reported at the same institution during 1998-2007. Cytopathology 2011, 22(June (3)):164-173.
8. Huang Y., Prasad M., Lemon W.J., Hampel H., Wright F.A., Kornacker K., et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc. Natl. Acad. Sci. USA 2001, 98(December (26)):15044-15049.
9. Fluge O., Bruland O., Akslen L.A., Lillehaug J.R., Varhaug J.E. Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid 2006, 16(February (2)):161-175.
10. Puxeddu E., Moretti S., Elisei R., Romei C., Pascucci R., Martinelli M., et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J. Clin. Endocr. Metab. 2004, 89(May (5)):2414-2420.
11. Kondo T., Nakazawa T., Murata S.I., Kurebayashi J., Ezzat S., Asa S.L., et al. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. Hum. Pathol. 2007, 38(December (12)):1810-1818.
12. Watanabe R., Hayashi Y., Sassa M., Kikumori T., Imai T., Kiuchi T., et al. Possible involvement of BRAFV600E in altered gene expression in papillary thyroid cancer. Endocr. J. 2009, 56(3):407-414.
13. Sapio M.R., Guerra A., Posca D., Limone P.P., Deandrea M., Motta M., et al. Combined analysis of galectin-3 and BRAF(V600E) improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocr. Relat. Cancer 2007, 14(December (4)):1089-1097.
14. Franzoni A., Dima M., D'Agostino M., Puppin C., Fabbro D., Di Loreto C., et al. Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation. Thyroid 2009, 19(March (3)):247-255.
15. Romei C., Ciampi R., Faviana P., Agate L., Molinaro E., Bottici V., et al. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr. Relat. Cancer 2008, 15(June (2)):511-520.
16. Espadinha C., Santos J.R., Sobrinho L.G., Bugalho M.J. Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAFV600E mutation dependency. Clin. Endocrinol. (Oxf.) 2009, 70(April (4)):629-635.
17. Su F., Viros A., Milagre C., Trunzer K., Bollag G., Spleiss O., et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 2012, 366(January (3)):207-215.
18. Wu S.Y., Lan S.H., Cheng D.E., Chen W.K., Shen C.H., Lee Y.R., et al. Ras-related tumorigenesis is suppressed by BNIP3-mediated autophagy through inhibition of cell proliferation. Neoplasia 2011, 13(December (12)):1171-1182.
19. Castro A.F., Campos T., Babcock J.T., Armijo M.E., Martinez-Conde A., Pincheira R., et al. M-Ras induces Ral and JNK activation to regulate MEK/ERK-independent gene expression in MCF-7 breast cancer cells. J. Cell. Biochem. 2011, 113(4):1253-1264.
20. Wacholder S., Chanock S., Garcia-Closas M., El ghormli L., Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J. Natl. Cancer Inst. 2004, 96(March (6)):434-442.
21. Carpi A., Mechanick J.I., Saussez S., Nicolini A. Thyroid tumor marker genomics and proteomics: diagnostic and clinical implications. J. Cell. Physiol. 2010, 224(September (3)):612-619.
22. Nikiforov Y.E. Molecular diagnostics of thyroid tumors. Arch. Pathol. Lab. Med. 2011, 135(May (5)):569-577.
23. Nucera C., Lawler J., Hodin R., Parangi S. The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?. Oncotarget 2010, 1(December (8)):751-756.
24. Mesa C., Mirza M., Mitsutake N., Sartor M., Medvedovic M., Tomlinson C., et al. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res. 2006, 66(July (13)):6521-6529.
25. Frasca F., Nucera C., Pellegriti G., Gangemi P., Attard M., Stella M., et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr. Relat. Cancer 2008, 15(March (1)):191-205.
26. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr. Rev. 2007, 28(December (7)):742-762.
27. Mitsutake N., Knauf J.A., Mitsutake S., Mesa C., Zhang L., Fagin J.A. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res. 2005, 65(March (6)):2465-2473.
28. Chou C.K., Chen R.F., Chou F.F., Chang H.W., Chen Y.J., Lee Y.F., et al. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid 2010, 20(May (5)):489-494.